The European Genomic Medicine Consortium (EGMEDC)

Accelerating the Clinical Translation of CRISPR and Genetic Medicines Across Europe

Who we are

The European Genomic Medicine Consortium (EGMEDC) is a pan-European, non-profit initiative convened by CRISPR Medicine News (CMN).

------

Our Mission

Our mission is to unite and empower clinical, academic, regulatory, and industry stakeholders to advance the development and delivery of CRISPR-based and related genetic therapies across Europe.

By aligning these efforts, we aim to establish a coordinated, ethical, and sustainable ecosystem for the clinical translation of genomic medicines - ensuring timely, safe, and equitable access for patients.

------

Strategic Aims

• Clinical Coordination and Implementation: Aligning cross-border trials, data sharing, and long-term monitoring (CMN Trial Database).
• Infrastructure Mapping and Creation: Connecting Europe's fragmented screening, gene and cell therapy capabilities and implementing joint clinical-grade tools and protocols.
• Policy & Regulation: Harmonizing ethics, health technology assessment (HTA), and European Medicines Agency (EMA) regulatory pathways.
• Access & Reimbursement: Supporting scalable and fair access models across EU member states.
• Industry + Public Collaboration: Bridging biotech, academic networks, national programs, and European initiatives.
• Annual Convening Power: Anchored by CRISPRMED - Europe’s leading genomic medicine conference in Copenhagen, where EGMEDC will have its annual meeting.

------

"Learn - Innovate - Access"

Supporters (early)

The EU Genomic Medicine Consortium (EGMEDC) is currently in the early development phase. The following organisations have expressed non-binding interest in supporting the initiative and contributing to its emerging structure. Their potential roles reflect areas of alignment and strategic interest, and will be further defined during the formalisation of the consortium. This list will be updated every week.

• Industry: Bayer Medicine, Chiesi
• Academic / Clinical: UMC Amsterdam, CCIT-DK
• Dissemination: CRISPR Medicine News, CMN (CMN will host quarterly interviews with EGMEDC members)
• Data Intelligence & Infrastructure: CMN Trial Database 2.0 (updated version will be available for EGMEDC members)
• Launch Platform / Annual Meeting: The annual CRISPRMED Conference, Cph, Denmark
• Legacy: Copenhagen Legacy Lab, CLL (CLL has expressed interest in supporting the long-term preservation and dissemination of outputs emerging from EGMEDC, serving as a potential anchor point for sustainability and institutional memory)
• Innovation: Innovation District Copenhagen, IDC
• Governance / Compliance / Accountant: Grant Thornton
• Governance / Legal: Lund Elmer Sandager